| Product Code: ETC11530850 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Poland Companion Diagnostics for Oncology Market Overview |
3.1 Poland Country Macro Economic Indicators |
3.2 Poland Companion Diagnostics for Oncology Market Revenues & Volume, 2021 & 2031F |
3.3 Poland Companion Diagnostics for Oncology Market - Industry Life Cycle |
3.4 Poland Companion Diagnostics for Oncology Market - Porter's Five Forces |
3.5 Poland Companion Diagnostics for Oncology Market Revenues & Volume Share, By Diagnostic Type, 2021 & 2031F |
3.6 Poland Companion Diagnostics for Oncology Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.7 Poland Companion Diagnostics for Oncology Market Revenues & Volume Share, By Sample Type, 2021 & 2031F |
3.8 Poland Companion Diagnostics for Oncology Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Poland Companion Diagnostics for Oncology Market Revenues & Volume Share, By Technology, 2021 & 2031F |
4 Poland Companion Diagnostics for Oncology Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Poland |
4.2.2 Growing adoption of personalized medicine in oncology |
4.2.3 Advancements in companion diagnostics technology |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for companion diagnostics |
4.3.2 High costs associated with companion diagnostics tests |
4.3.3 Limited reimbursement policies for companion diagnostics in Poland |
5 Poland Companion Diagnostics for Oncology Market Trends |
6 Poland Companion Diagnostics for Oncology Market, By Types |
6.1 Poland Companion Diagnostics for Oncology Market, By Diagnostic Type |
6.1.1 Overview and Analysis |
6.1.2 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Diagnostic Type, 2021 - 2031F |
6.1.3 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Molecular Diagnostics, 2021 - 2031F |
6.1.4 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Immunodiagnostics, 2021 - 2031F |
6.1.5 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Genetic Testing, 2021 - 2031F |
6.1.6 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Imaging-Based Diagnostics, 2021 - 2031F |
6.2 Poland Companion Diagnostics for Oncology Market, By Cancer Type |
6.2.1 Overview and Analysis |
6.2.2 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Lung Cancer, 2021 - 2031F |
6.2.3 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.2.4 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.2.5 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Prostate Cancer, 2021 - 2031F |
6.3 Poland Companion Diagnostics for Oncology Market, By Sample Type |
6.3.1 Overview and Analysis |
6.3.2 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Blood, 2021 - 2031F |
6.3.3 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Tissue, 2021 - 2031F |
6.3.4 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Saliva, 2021 - 2031F |
6.3.5 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Urine, 2021 - 2031F |
6.4 Poland Companion Diagnostics for Oncology Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
6.4.4 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.4.5 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Pharmaceuticals, 2021 - 2031F |
6.5 Poland Companion Diagnostics for Oncology Market, By Technology |
6.5.1 Overview and Analysis |
6.5.2 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By PCR-Based, 2021 - 2031F |
6.5.3 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By ELISA, 2021 - 2031F |
6.5.4 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By Microfluidics, 2021 - 2031F |
6.5.5 Poland Companion Diagnostics for Oncology Market Revenues & Volume, By AI-Based Analysis, 2021 - 2031F |
7 Poland Companion Diagnostics for Oncology Market Import-Export Trade Statistics |
7.1 Poland Companion Diagnostics for Oncology Market Export to Major Countries |
7.2 Poland Companion Diagnostics for Oncology Market Imports from Major Countries |
8 Poland Companion Diagnostics for Oncology Market Key Performance Indicators |
8.1 Adoption rate of companion diagnostics in oncology treatments |
8.2 Number of partnerships between diagnostic companies and pharmaceutical firms |
8.3 Rate of development and approval of new companion diagnostics tests |
9 Poland Companion Diagnostics for Oncology Market - Opportunity Assessment |
9.1 Poland Companion Diagnostics for Oncology Market Opportunity Assessment, By Diagnostic Type, 2021 & 2031F |
9.2 Poland Companion Diagnostics for Oncology Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
9.3 Poland Companion Diagnostics for Oncology Market Opportunity Assessment, By Sample Type, 2021 & 2031F |
9.4 Poland Companion Diagnostics for Oncology Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Poland Companion Diagnostics for Oncology Market Opportunity Assessment, By Technology, 2021 & 2031F |
10 Poland Companion Diagnostics for Oncology Market - Competitive Landscape |
10.1 Poland Companion Diagnostics for Oncology Market Revenue Share, By Companies, 2024 |
10.2 Poland Companion Diagnostics for Oncology Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here